Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Ibrutinib associated with decreased circulating malignant cells and restored T-cell function in CLL patients

Key clinical point: Ibrutinib normalized abnormal immune cell counts to levels similar to those of age-matched healthy donors.

Major finding: Ibrutinib significantly restored T-cell proliferative ability, degranulation, and cytokine secretion.

Study details: Circulating counts of 21 immune blood cell subsets were compared between 55 patients with relapsed/refractory (R/R) CLLl and 50 previously untreated CLL patients, as compared with 20 untreated age-matched healthy donors.

Disclosures: The study was funded by Pharmacyclics, an AbbVie Company. Ms.. Solman is an employee of Translational Medicine, Pharmacyclics, Sunnyvale, Calif, as were several other authors.

Citation:

Solman IG et al. Leuk Res. 2020;97: doi: 10.1016/j.leukres.2020.106432.